AU Patent

AU2013302269A1 — Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors

Assigned to Trillium Therapeutics ULC · Expires 2015-03-12 · 11y expired

What this patent protects

The present application relates to novel fiuorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application …

USPTO Abstract

The present application relates to novel fiuorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof:

Drugs covered by this patent

Patent Metadata

Patent number
AU2013302269A1
Jurisdiction
AU
Classification
—
Expires
2015-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Trillium Therapeutics ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.